PMID- 11694788
OWN - NLM
STAT- MEDLINE
DCOM- 20011228
LR  - 20221207
IS  - 0030-2414 (Print)
IS  - 0030-2414 (Linking)
VI  - 61 Suppl 2
DP  - 2001
TI  - New combinations with Herceptin in metastatic breast cancer.
PG  - 50-7
AB  - Preclinical data indicate that trastuzumab (Herceptin) has the potential for 
      synergistic or additive effects in combination with therapies including 
      chemotherapy and hormonal agents, providing the rationale for a number of 
      clinical trials in women with HER2-positive metastatic breast cancer. A recently 
      reported phase II trial has demonstrated that trastuzumab plus vinorelbine is 
      both effective (overall response rate 75%) and well tolerated, with the major 
      side effects being typical of single-agent vinorelbine. Other combinations of 
      trastuzumab with a variety of other chemotherapeutic and hormonal agents are also 
      being assessed. In an effort to overcome the cardiotoxicity observed with 
      trastuzumab plus doxorubicin in the pivotal phase III trial, combination regimens 
      involving potentially less toxic anthracyclines such as epirubicin and liposomal 
      formulations of doxorubicin are ongoing. In addition, trials are investigating 
      whether trastuzumab can reverse the resistance to hormonal therapy that develops 
      in most women with metastatic breast cancer. These and other studies will 
      identify the regimens that produce the best outcomes with the fewest possible 
      side effects in women with HER2-positive breast cancer.
CI  - Copyright 2001 S. Karger AG, Basel
FAU - Winer, E P
AU  - Winer EP
AD  - Dana-Farber Cancer Institute, Boston, Mass 02115, USA. ewiner@partners.org
FAU - Burstein, H J
AU  - Burstein HJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Nitriles)
RN  - 0 (Organoplatinum Compounds)
RN  - 0 (Triazoles)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 2Z07MYW1AZ (Anastrozole)
RN  - 3Z8479ZZ5X (Epirubicin)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 905Z5W3GKH (Thiotepa)
RN  - P188ANX8CK (Trastuzumab)
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q6C979R91Y (Vinorelbine)
RN  - U3P01618RT (Fluorouracil)
RN  - YL5FZ2Y5U1 (Methotrexate)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Anastrozole
MH  - Antibodies, Monoclonal/administration & dosage/adverse effects/*pharmacology
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents, Hormonal/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/mortality/pathology
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Cyclophosphamide/administration & dosage/pharmacology
MH  - Deoxycytidine/*analogs & derivatives/antagonists & inhibitors/pharmacology
MH  - Doxorubicin/administration & dosage/pharmacology
MH  - Drug Interactions
MH  - Drug Synergism
MH  - Epirubicin/administration & dosage/pharmacology
MH  - Female
MH  - Fluorouracil/antagonists & inhibitors/pharmacology
MH  - Heart Diseases/chemically induced
MH  - Hematologic Diseases/chemically induced
MH  - Humans
MH  - Methotrexate/administration & dosage/antagonists & inhibitors
MH  - Neoplasm Metastasis
MH  - Nitriles/administration & dosage
MH  - Organoplatinum Compounds/administration & dosage
MH  - Paclitaxel/administration & dosage/pharmacology
MH  - Tamoxifen/administration & dosage
MH  - Thiotepa/administration & dosage/pharmacology
MH  - Trastuzumab
MH  - Treatment Outcome
MH  - Triazoles/administration & dosage
MH  - Vinblastine/administration & dosage/*analogs & derivatives/pharmacology
MH  - Vinorelbine
MH  - Gemcitabine
RF  - 41
EDAT- 2001/11/06 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/06 10:00
PHST- 2001/11/06 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/06 10:00 [entrez]
AID - 55402 [pii]
AID - 10.1159/000055402 [doi]
PST - ppublish
SO  - Oncology. 2001;61 Suppl 2:50-7. doi: 10.1159/000055402.